Kymera Therapeutics Inc
Officers & Directors
Nello Mainolfi, Ph.D. President and Chief Executive Officer Leigh Morgan Director John M. Maraganore, Ph.D. Director Elena Ridloff, CFA Director Pamela Esposito, Ph.D. Director Bruce Jacobs, CFA, MBA Chief Financial Officer Bruce Booth, DPhil Chair of the Board of Directors Gorjan Hrustanovic, Ph.D. Director Victor Sandor Director Joanna Horobin, MB, ChB Director Jeff Albers, MBA Director ,
Kymera Therapeutics Inc currently has 238 employees.
News about Kymera Therapeutics Inc Key Personnel |
Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer Amidst Milestones and Financial RealitiesKymera Therapeutics, Inc. (NASDAQ: KYMR), a pioneering biopharmaceutical company headquartered in Watertown, Massachusetts, has recently announced the appointment of Noah Goodman, M.B.A. as its new Chief Business Officer. This strategic move comes at a crucial juncture for Kymera, which is making notable advancements in the realm of oral small molecule degrader medicines targeted at immunological diseases. With over a decade of diverse experience in the life sciences sector, Goodman’s expertise is expected to enhance Kymera’s business development strategies significantly. In his new role, Goodman...
|
Kymera Therapeutics: Pioneering a New Era in Oral Immunology Amidst Financial ChallengesOverview of Facts:1. Recent FDA Clearance: Kymera Therapeutics received FDA clearance for its Investigational New Drug (IND) application for KT-621, marking a significant milestone as the first oral STAT6 degrader targeting Th2-mediated diseases. 2. Clinical Development: The Phase 1 trial for KT-621 is currently ongoing with results anticipated in the second quarter of 2025. This trial involves healthy volunteers and aims to assess the safety and pharmacokinetics of the drug.3. Financial Performance: The company reported a cumulative net loss of $167 million over the 12 months ending in Q3 2024, leading to a negative r...
|
In a groundbreaking move, Kymera Therapeutics, a leading biotechnology company, has laid out its key objectives and strategic vision for the year 2024. Combining innovative science with a patient-centric approach, Kymera aims to advance its portfolio of Immunology and Oncology programs. The company s recent announcement of the expected completion of enrollment and topline data from the Phase 2 HS and AD studies of its IRAK4 oral degrader, KT-474 (SAR444656), reaffirms its commitment to transforming the landscape of healthcare.
Overview of Kymera Therapeutics:
Kymera Therapeutics is at the forefront of developing novel therapeutics that harness the body s innate cellular machinery to target ...
|
Kymera Therapeutics Announces Successful Pricing of $275 Million Public Offering, Setting the Stage for Continued Progress in Targeted Protein Degradation
WATERTOWN, Mass., January 5, 2024 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a pioneering clinical-stage biopharmaceutical company leveraging targeted protein degradation (TPD) to develop a new class of small molecule medicines, is pleased to announce the successful pricing of its underwritten public offering. The company is offering $275 million worth of shares of its common stock, alongside pre-funded warrants to purchase additional shares of common stock. This milestone not only signifies confidence in Kymera s innovative approach but also provides...
|
|
|
